Updates are available Correction dated 2024-09-10
Click to view Correction: https://doi.org/10.1038/s43587-024-00717-w
-
Authors
Austin, Thomas R.
Nethander, Maria https://orcid.org/0000-0003-3688-906X
Fink, Howard A. https://orcid.org/0000-0002-5985-5447
Törnqvist, Anna E. https://orcid.org/0000-0003-2621-9038
Jalal, Diana I.
Buzkova, Petra
Barzilay, Joshua I.
Carbone, Laura https://orcid.org/0000-0003-1007-5949
Gabrielsen, Maiken E.
Grahnemo, Louise https://orcid.org/0000-0001-5276-6612
Lu, Tianyuan https://orcid.org/0000-0002-5664-5698
Hveem, Kristian
Jonasson, Christian https://orcid.org/0000-0002-7694-6025
Kizer, Jorge R.
Langhammer, Arnulf
Mukamal, Kenneth J. https://orcid.org/0000-0001-8450-6970
Gerszten, Robert E. https://orcid.org/0000-0002-6767-7687
Psaty, Bruce M. https://orcid.org/0000-0002-7278-2190
Robbins, John A.
Sun, Yan V. https://orcid.org/0000-0002-2838-1824
Skogholt, Anne Heidi https://orcid.org/0000-0001-7466-0405
Kanis, John A.
Johansson, Helena
Åsvold, Bjørn Olav https://orcid.org/0000-0003-3837-2101
Valderrabano, Rodrigo J. https://orcid.org/0000-0002-4910-3997
Zheng, Jie https://orcid.org/0000-0002-6623-6839
Richards, J. Brent https://orcid.org/0000-0002-3746-9086
Coward, Eivind
Ohlsson, Claes https://orcid.org/0000-0002-9633-2805
- License Information
-
More Information
Article History
Received: 17 March 2024
Accepted: 1 May 2024
First Online: 27 May 2024
Change Date: 10 September 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43587-024-00717-w
Competing interests
: B.M.P. serves on the Yale Open Data Access Project funded by Johnson & Johnson, which had no impact on this paper. J.B.R. is founder and CEO of 5 Prime Sciences, which provides research services for biotech, pharma and venture capital companies for projects unrelated to this research. T.L. is an employee of 5 Prime Sciences. J.B.R. has served as an advisor to GSK and Deerfield Capital. The institution of J.B.R. has received investigator-initiated grant funding from Eli Lilly, GSK and Biogen for projects unrelated to this research. J.R.K. reports stock ownership in Abbott, AbbVie, Bristol-Myers Squibb, Johnson & Johnson, Medtronic, Merck and Pfizer. J.A.K. is a director of Osteoporosis Research, which maintains and develops FRAX. C.O. is an applicant on filed patent applications on the effect of probiotics on bone metabolism. The other authors declare no competing interests.
